Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study
NCT05906316 · View on ClinicalTrials.gov ↗
Study Summary
To gain insight in the effectiveness of, adherence and adjustments to guideline-based three-drug antimycobacterial therapy in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) during the first 6 months of treatment.
Conditions Studied
Study Locations (11)
Other
- UZ Leuven — Leuven
- University Hospital Center Zagreb — Zagreb
- Aarhus University Hospital — Aarhus
- Rasmus Rude Laub — Hellerup
- University Hospital Frankfurt — Frankfurt
- Fukujuji Hospital — Tokyo
- Radboud University Medical Center — Nijmegen
- Seoul National University Hospital — Seoul
- Hospital Clínic de Barcelona — Barcelona
Oregon
- Oregon Science and Health University — Portland
Alberta
- University of Calgary — Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-07-01 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05906316
The ClinicalTrials.gov registry entry for NCT05906316 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radboud University Medical Center, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Mycobacterium Avium Complex Pulmonary Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05906316 reports 11 study locations spanning 3 distinct geographic areas — top geographies include Other, Oregon, Alberta. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05906316 about?
NCT05906316 is a clinical study titled "A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study". To gain insight in the effectiveness of, adherence and adjustments to guideline-based three-drug antimycobacterial therapy in patients with Mycobacterium avium complex pulmonary disease (MAC-PD) during the first 6 months of treatment.
What is the current status of trial NCT05906316?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-07-01. Estimated completion is 2026-07-01.
What conditions does trial NCT05906316 study?
This clinical trial studies the following conditions: Mycobacterium Avium Complex Pulmonary Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT05906316?
This trial is sponsored by Radboud University Medical Center, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05906316 being conducted?
This trial has 11 study locations across Oregon, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.